Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  Oades, Robert D ^a   Dauvermann, Maria R ^a   Schimmelmann, Benno G ^c   Schwarz, Markus J ^b   Myint, Aye Mu ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 1BETA; INTERLEUKIN 2; KYNURENINE; METHYLPHENIDATE; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA; 3 HYDROXYKYNURENINE; 3-HYDROXYKYNURENINE; AMINO ACID; CENTRAL STIMULANT AGENT; DRUG DERIVATIVE; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; TRYPTOPHAN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CONDUCT DISORDER; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; GLIA; HUMAN; MALE; NEUROPROTECTION; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; TRYPTOPHAN METABOLISM; ADOLESCENT; BLOOD; BRAIN; CYTOLOGY; ENERGY METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY; PILOT STUDY;

ADOLESCENT; AMINO ACIDS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CYTOKINES; ENERGY METABOLISM; FEMALE; HUMANS; KYNURENINE; MALE; NERVE GROWTH FACTORS; NEUROGLIA; PILOT PROJECTS; S100 PROTEINS; TRYPTOPHAN;

EID: 77952695803     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-6-29     Document Type: Article

References (100)

1. Kuntsi J, Andreou P, Ma J, Börger NA, Meere JJ. Testing assumptions for endophenotype studies in ADHD: Reliability and validity of tasks in a general population sample. BMC psychiatry 2005, 5:40. 10.1186/1471-244X-5-40, 1291376, 16262903.
2. Klein C, Wendling K, Huettner P, Ruder H, Peper M. Intra-subject variability in attention-deficit hyperactivity disorder (ADHD). Biol Psychiatry 2006, 60:1088-1097. 10.1016/j.biopsych.2006.04.003, 16806097.
3. Querne L, Berquin P. Distinct Response Time Distributions in Attention Deficit Hyperactivity Disorder Subtypes. J Atten Disord 2009, 13:66-77. 10.1177/1087054708323006, 18725655.
4. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nature Reviews: Neuroscience 2002, 3:617-628.
5. Uebel H, Albrecht B, Asherson P, Boerger N, Butler L, Chen W, et al. Performance variability, impulsivity errors and the impact of incentives as gender-independent endophenotypes for ADHD. J Child Psychol Psychiat 2009,
6. Russell VA, Oades RD, Tannock R, Auerbach J, Killeen PR, Johansen EB, et al. Response variability in attention-deficit/hyperactivity disorder: a neuronal and glial energetics hypothesis. Behav Brain Funct 2006, 2:30. 10.1186/1744-9081-2-30, 1624838, 16925830.
7. Tanaka Y, Marumo T, Omura T, Yoshida S. Relationship between cerebrospinal and peripheral S100B levels after focal cerebral ischemia in rats. Neurosci Lett 2008, 436:40-43. 10.1016/j.neulet.2008.02.056, 18359161.
8. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC neurosci 2007, 8:2. 10.1186/1471-2202-8-2, 1769505, 17199889.
9. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364. 10.1016/j.pnpbp.2006.09.013, 17081670.
10. Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull 2001, 56:413-424. 10.1016/S0361-9230(01)00614-1, 11750787.
11. Tanaka Y, Marumo T, Omura T, Yoshida S. Early increases in serum S100B are associated with cerebral hemorrhage in a rat model of focal cerebral ischemia. Brain Res 2008, 1227:248-254. 10.1016/j.brainres.2008.06.076, 18621038.
12. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LMV, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41:523-529. 10.1016/j.jpsychires.2006.07.013, 16956621.
13. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003, 13:235-239. 10.1016/S0924-977X(03)00016-6, 12888182.
14. Netto CB, Portela LV, Ferreira CT, Kieling C, Matte U, Felix T, et al. Ontogenetic changes in serum S100B in Down syndrome patients. Clin Biochem 2005, 38:433-435. 10.1016/j.clinbiochem.2004.12.014, 15820773.
15. Steiner J, Bernstein HG, Farkas N, Winter J, Mawrin C, Myint AM, et al. S100B immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. Eur Arch Psychiatry Clin Neurosci 2008, 258:21. 10.1007/s00406-007-1005-y, 18344046.
16. Kaiser S, Roth A, Rentrop M, Friederich HC, Bender S, Weisbrod M. Intra-individual reaction time variability in schizophrenia, depression and borderline personality disorder. Brain Cogn 2008, 66:73-82. 10.1016/j.bandc.2007.05.007, 17604894.
17. Gerlach R, Demel G, König HG, Gross U, Prehn JHM, Raabe A, et al. Active secretion of S100B from astrocytes during metabolic stress. Neurosci 2006, 141:1697-1701.
18. Hove DLA, Steinbusch HWM, Bruchettini M, Gazzolo D, Frulio R, Scheepens A, et al. Prenatal stress reduces S100B in the neonatal rat hippocampus. Neuroreport 2006, 17:1077-1080. 10.1097/01.wnr.0000223391.74575.c9, 16791107.
19. Nardin P, Tortorelli L, Quincozes-Santos A, de Almeida LMV, Leite MC, Thomazi AP, et al. S100B Secretion in Acute Brain Slices: Modulation by Extracellular Levels of Ca2+ and K+. Neurochem Res 2009, 34:1603-1611. 10.1007/s11064-009-9949-0, 19288274.
20. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993, 45:309-379.
21. Oades RD. Dopamine may be 'hyper' with respect to noradrenaline metabolism, but 'hypo' with respect to serotonin metabolism in children with ADHD. Behav Brain Res 2002, 130:97-101. 10.1016/S0166-4328(01)00440-5, 11864724.
22. Oades RD. Dopamine-serotonin interactions in attention-deficit/hyperactivity disorder (ADHD). Prog Brain Res 2008, 172:543-565. full_text, 18772050.
23. Uzbekov MG. Hyperkinetic syndrome as a manifestation of a disturbance of metabolism and mental development. Attention-Deficit/Hyperactivity Disorder and the Hyperkinetic Syndrome: Current Ideas and Ways Forward 2006, 133-154. Hauppauge, NewYork: Nova Science Publishers, Inc., Oades RD.
24. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, et al. Characterization of the Kynurenine Pathway in Human Neurons. J Neurosci 2007, 27:12884-12892. 10.1523/JNEUROSCI.4101-07.2007, 18032661.
25. Leonard BE, Myint AM. Inflammation and depression: is there a causal connection with dementia?. Neurotox Res 2006, 10:149-160. 10.1007/BF03033243, 17062376.
26. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004, 129:267-272. 10.1016/j.psychres.2004.08.005, 15661320.
27. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch HWM, Leonard BE. Kynurenine pathway in major depression: Evidence of impaired neuroprotection. J Affect Disord 2007, 98:143-151. 10.1016/j.jad.2006.07.013, 16952400.
28. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55:241-269. 10.1124/pr.55.2.4, 12773629.
29. Mittelman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997, 159:2994-2999.
30. Segman RH, Meltzer A, Gross-Tsur V, Kosov A, Frisch A, Inbar E, et al. Preferential transmission of interleukin-1 receptor antagonist alleles in attention deficit hyperactivity disorder. Mol Psychiatry 2002, 7:72-74. 10.1038/sj/mp/4000919, 11803448.
31. Misener VL, Schachar RJ, Ickowicz A, Malone M, Roberts W, Tannock R, et al. Replication test for association of the IL-1 receptor antagonist gene, IL1RN, with attention-deficit/hyperactivity disorder. Neuropsychobiol 2004, 50:231-234.
32. Drtilkova I, Sery O, Theiner P, Uhrova A, Zackova M, Balastikova B, et al. Clinical and molecular genetic markers of ADHD in children. Neuroendocrinol Lett 2008, 29:320-327.
33. Lasky-Su J, Anney RJL, Neale BM, Franke B, Zhou K, Maller JB, et al. Genome-wide association scan of the time to onset of Attention Deficit Hyperactivity Disorder. Am J Med Genet B 2008, 147B:1355-1358.
34. Lasky-Su J, Neale BM, Franke B, Anney RJL, Zhou K, Maller JB, et al. Genome-wide association scan of quantitative traits for Attention Deficit Hyperactivity Disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B 2008, 147B:1345-1354.
35. Murin R, Hamprecht B. Metabolic and Regulatory Roles of Leucine in Neural Cells. Neurochem Res 2008, 33:279-284. 10.1007/s11064-007-9444-4, 17721727.
36. Murin R, Mohammadi G, Leibfritz D, Hamprecht B. Glial Metabolism of Isoleucine. Neurochem Res 2009, 34:194-204. 10.1007/s11064-008-9840-4, 18787950.
37. Murin R, Mohammadi G, Leibfritz D, Hamprecht B. Glial Metabolism of Valine. Neurochem Res 2009, 34:1195-1203. 10.1007/s11064-008-9895-2, 19127430.
38. Taylor EA, Sandberg S, Thorley G, Giles S. The epidemiology of childhood hyperactivity 1991, Oxford, UK: Oxford University Press.
39. Chen W, Taylor EA. Parental Account of Children's Symptoms (PACS), ADHD phenotypes and its application to molecular genetic studies. Attention-Deficit/Hyperactivity Disorder and the Hyperkinetic Syndrome: Current Ideas and Ways Forward 2006, 3-20. Hauppauge, NY 11788: Nova Science Publishing Inc., Oades RD.
40. Conners CK. Manual for Conners' rating scales 2002, NY: Multi-Health Systems Inc., Tonoawanda N.
41. Weiss RH. CFT-20-R: Grundintelligenztest 1996, Göttingen: Hogrefe Verlag GmbH & Co KG, 2.
42. Kaufman AS, Kaufman NL. Kaufman-Assessment Battery for Children 2001, Frankfurt am Main, Germany: Swets & Zeitlinger, Melchers P, Preuß U, 5.
43. Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ. Cytokines and tryptophan/kynurenine metabolism in attention-deficit/hyperactivity disorder (ADHD): an exploration of potential associations with symptoms, sustained attention and features of pregnancy. Behav Brain Funct 2010,
44. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HWM, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007, 102:65-72. 10.1016/j.jad.2006.12.008, 17270276.
45. Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 2006, 7:423-436. 10.1038/nrn1928, 2062484, 16715052.
46. Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q, et al. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia 2008, 56:686-698. 10.1002/glia.20646, 18293407.
47. Ling ZD, Potter ED, Lipton JW, Carvey PM. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 1998, 149:411-423. 10.1006/exnr.1998.6715, 9500954.
48. Kreis R, Hofmann L, Kuhlmann B, Bossi E, Hüppi PS. Brain metabolite composition during early human brain development as measured by quantitative in vivo 1 H magnetic resonance spectroscopy. Magn Reson Med 2002, 48:949-958. 10.1002/mrm.10304, 12465103.
49. Courvoisie H, Hooper SR, Fine C, Kwock L, Castillo M. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. J Neuropsychiatry Clin Neurosci 2004, 16:63-69.
50. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, et al. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry 2006, 163:316-318. 10.1176/appi.ajp.163.2.316, 16449488.
51. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased Prefrontal Myo-Inositol in Major Depressive Disorder. Biol Psychiatry 2005, 57:1526-1534. 10.1016/j.biopsych.2005.02.027, 15953489.
52. Oades RD. The role of the serotonin system in ADHD: treatment implications. Expert Rev Neurotherapeutics 2007, 7:1357-1374.
53. Oades RD. Function and dysfunction of monoamine interactions in children and adolescents with AD/HD. Neurotransmitter interactions and cognitive function 2006, 207-244. Basel: Birkhäuser Verlag, Levin ED.
54. Sonuga-Barke EJS, Oades RD, Psychogiou L, Chen W, Franke B, Buitelaar JK, et al. Dopamine and serotonin transporter genotypes moderate sensitivity to maternal expressed emotion: The case of conduct and emotional problems in Attention Deficit/Hyperactivity Disorder. J Child Psychol Psychiatry 2009, 50:1052-1063. 10.1111/j.1469-7610.2009.02095.x, 19490304.
55. Lanier LP, Dunn AJ, Van Hartesveldt C. Development of neurotransmitters and their function in brain. Rev Neurosci 1976, 2:195-256.
56. Bonnin A, Torii M, Wang L, Rakic P, Levitt P. Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat Neurosci 2007, 10:588-597. 10.1038/nn1896, 17450135.
57. Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29:529-538. 10.1111/j.1460-9568.2008.06594.x, 19187269.
58. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neurosci 2009, 159:196-203.
59. Livingstone PD, Srinivasan J, Kew JNC, Dawson LA, Gotti C, Moretti M, et al. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci 2009, 29:539-550. 10.1111/j.1460-9568.2009.06613.x, 19187266.
60. di Luccio E, Wilson DK. Comprehensive X-ray structural studies of the quinolinate phosphoribosyl transferase (BNA6) from Saccharomyces cerevisiae. Biochemistry 2008, 47:4039-4050. 10.1021/bi7020475, 18321072.
61. Huttenlocher PR. Synapse elimination and plasticity in developing human cerebral cortex. Am J Ment Defic Res 1984, 88:488-496.
62. Bourgeois JP, Rakic P. Changes of synaptic density in the primary visual cortex of the macaque monkey from fetal to adult stage. J Neurosci 1993, 13:2801-2820.
63. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci (USA) 2007, 104:19649-19654.
64. Fernandez A, Quintero J, Hornero R, Zuluaga P, Navas M, Gomez C, et al. Complexity Analysis of Spontaneous Brain Activity in Attention-Deficit/Hyperactivity Disorder: Diagnostic Implications. Biol Psychiatry 2009, 65:571-577. 10.1016/j.biopsych.2008.10.046, 19103438.
65. OConnor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon- and Tumor Necrosis Factor- Mediate the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-Like Behavior in Mice in Response to Bacillus Calmette-Guérin. J Neurosci 2009, 29:4200-4209. 10.1523/JNEUROSCI.5032-08.2009, 2835569, 19339614.
66. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Immunol 1993, 47:169-176.
67. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994, 179:53-56. 10.1016/0304-3940(94)90933-4, 7845624.
68. Waguespack PJ, Banks WA, Kastin AJ. Interleukin-2 does not cross the blood-brain barrier by a saturable transport system. Brain Res Bull 1994, 34:103-109. 10.1016/0361-9230(94)90005-1, 8044683.
69. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33:355-366. 10.1016/j.neubiorev.2008.10.005, 18996146.
70. Ye JH, Zalcman SS, Tao L. Kainate-activated currents in the ventral tegmental area of neonatal rats are modulated by interleukin-2. Brain Res 2005, 1049:227-233. 10.1016/j.brainres.2005.05.016, 15935333.
71. Lacosta S, Merali Z, Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomod 2000, 8:83-90.
72. Braida D, Sacerdote P, Panerai AE, Bianchi M, Aloisi AM, Iosue S, et al. Cognitive function in young and adult IL(interleukin)-6 deficient mice. Behav Brain Res 2004, 153:423-429. 10.1016/j.bbr.2003.12.018, 15265638.
73. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. Biol Psychiatry 2008, 63:1022-1029. 10.1016/j.biopsych.2007.12.007, 18242584.
74. Fogal B, Hewett SJ. Interleukin-1ß: a bridge between inflammation and excitotoxicity?. J Neurochem 2008, 106:1-23. 10.1111/j.1471-4159.2008.05315.x, 18315560.
75. Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinol 2004, 29:1119-1128.
76. Anisman H, Gibb J, Hayley S. Influence of continuous infusion of interleukin-1ß on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacol 2008, 199:231-244.
77. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine Mechanisms of Central Sensitization: Distinct and Overlapping Role of Interleukin-1ß, Interleukin-6, and Tumor Necrosis Factor- in Regulating Synaptic and Neuronal Activity in the Superficial Spinal Cord. J Neurosci 2008, 28:5189-5194. 10.1523/JNEUROSCI.3338-07.2008, 2408767, 18480275.
78. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C, Nielsen HH, et al. Microglia Protect Neurons against Ischemia by Synthesis of Tumor Necrosis Factor. J Neurosci 2009, 29:1319-1330. 10.1523/JNEUROSCI.5505-08.2009, 19193879.
79. Wang XQ, Peng YP, Lu JH, Cao BB, Qiu YH. Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK. Neurosci Lett 2009, 450:122-126. 10.1016/j.neulet.2008.11.051, 19061939.
80. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations. J Neurosci 1999, 19:5654-5665.
81. Baune BT, Wiede F, Braun A, Golledge J, Arolt V, Koerner H. Cognitive dysfunction in mice deficient for TNFα and its receptors. Am J Med Genet B 2008, 147B:1056-1064.
82. Rönnbäck L, Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 2004, 1:22. 10.1186/1742-2094-1-22, 533886, 15527505.
83. Di Filippo M, Sarchielli P, Picconi B, Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 2008, 29:402-412. 10.1016/j.tips.2008.06.005, 18617277.
84. Meyer U, Murray PJ, Urwyler A, Yee BK, Schedlowski M, Feldon J. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 2008, 13:208-221. 10.1038/sj.mp.4002042, 17579604.
85. Hirschberg DL, Yoles E, Belkin M, Schwartz M. Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. J Immunol 1994, 50:9-16.
86. Müller N. Antiinflammatory therapy in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 2008, 258:13.
87. Huang TL, Lee CT. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiat Clin Neurosci 2007, 61:415-420.
88. Hertz L, Gibbs ME. What learning in day-old chickens can teach a neurochemist: focus on astrocyte metabolism. J Neurochem 2009, 109:10-16. 10.1111/j.1471-4159.2009.05939.x, 19393003.
89. Ernst M, Zametkin AJ, Matochik JA, Schmidt M, Jons PH, Liebenauer LL, et al. Intravenous dextroamphetamine and brain glucose metabolism. Neuropsychopharmacol 1997, 17:391-401.
90. Todd RD, Botteron KN. Is attention-deficit/hyperactivity disorder an energy deficiency syndrome?. Biol Psychiatry 2001, 50:151-158. 10.1016/S0006-3223(01)01173-8, 11513813.
91. Balosini V, Monzani A, Rapa A, Vivenza D, Caristo E, Oderda G. Interleukin-10 and transforming growth factor-ß1 in cord blood: relationship with paternal allergy and cesarean section. Acta Paediatr 2009, 98:812-816. 10.1111/j.1651-2227.2008.01194.x, 19183122.
92. Little FF, Lynch E, Fine G, Center DM, Cruikshank WW. Tumor necrosis factor-alpha-induced synthesis of interleukin-16 in airway epithelial cells: priming for serotonin stimulation. Am J Respir Cell Mol Biol 2003, 28:354-362. 10.1165/rcmb.2002-0043OC, 12594062.
93. Deng JM, Shi HZ. Interleukin-16 in asthma. Chin Med J 2006, 119:1017-1025.
94. Rapp DJ. Does diet affect hypersensitivity?. J Learn Disabil 1978, 11:56-62.
95. Tryphonas H, Trites RL. Food allergy in children with hyperactivity, learning disabilities and/or minimal brain dysfunction. Ann Allergy 1979, 42:22-27.
96. Egger J, Carter CM, Graham PJ, Gumley D, Soothill JF. Controlled trial of oligoantigenic treatment in the hyperkinetic syndrome. Lancet 1985, 14:540-545.
97. Blank R, Remschmidt H. Hyperkinetic syndrome: the role of allergy among psychological and neurological factors. Eur Child Adolesc Psychiatry 1994, 3:220-228.
98. Miller AH, Maletic V, Raison CL. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry 2009, 65:732-741. 10.1016/j.biopsych.2008.11.029, 2680424, 19150053.
99. Oades RD, Dauvermann MR, Schwarz MJ, Myint AM. Does glial function underlie ADHD variability? Evidence from measures of S100B, interleukins, tryptophan metabolism and the kynurenine metabolic pathway. Neurol Psychiat Brain Res 2009, (Supplement 1):44.
100. Brauns H, Haun D, Steinmann S. The construction of an internationally comparable classification by class. Erwerbsstatistische Besonderheiten am Beispiel von Labour Force Surveys der Bundesrepublik Deutschland, Frankreichs, Großbritanniens und Ungarns, Mannheim, Germany 1997,